Drug Hepatotoxicity: Newer Agents

Clinics in Liver Disease

Volumn 21, Issue 1, 2017, Pages 115-134

  Bunchorntavakul, Chalermrat ^a,b   Reddy, K Rajender ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b RANGSIT UNIVERSITY   (Thailand)

Author keywords

Antibiotics; Anticoagulants; Antiplatelet; Antiretrovirals; Drug induced liver injury; Hepatotoxicity; Monoclonal antibodies; Tyrosine kinase inhibitors

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIRETROVIRUS AGENT; APIXABAN; AZITHROMYCIN; CEFAZOLIN; CEPHALOSPORIN DERIVATIVE; CLOPIDOGREL; DABIGATRAN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EDOXABAN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INFLIXIMAB; IPILIMUMAB; NEUROLEPTIC AGENT; PAROXETINE; PRASUGREL; PROTEIN TYROSINE KINASE INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RITUXIMAB; RIVAROXABAN; SERTRALINE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; TUMOR NECROSIS FACTOR INHIBITOR; UNINDEXED DRUG; XIMELAGATRAN; ANTIINFECTIVE AGENT; DRUG; MONOCLONAL ANTIBODY; NEW DRUG;

ACUTE LIVER FAILURE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; AUTOIMMUNE HEPATITIS; CHOLESTASIS; CHRONIC HEPATITIS B; CLINICAL TRIAL (TOPIC); DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRESS SYNDROME; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMBOLISM; EOSINOPHILIA; EPILEPSY; EXTRAPYRAMIDAL SYMPTOM; FATTY LIVER; FEVER; GENETIC ASSOCIATION; HEART INFARCTION; HEPATITIS; HEPATITIS B; HIGH RISK POPULATION; HUMAN; HYPERPLASIA; HYPERSENSITIVITY; HYPERTRANSAMINASEMIA; IMMUNOPATHOGENESIS; INTERSTITIAL NEPHRITIS; JAUNDICE; LIVER CELL DAMAGE; LIVER FAILURE; LIVER INJURY; LIVER TOXICITY; LUNG EMBOLISM; META ANALYSIS (TOPIC); MULTIPLE CYCLE TREATMENT; NODULAR REGENERATIVE HYPERPLASIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PORTAL HYPERTENSION; POSTMARKETING SURVEILLANCE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RHEUMATOID ARTHRITIS; SIALOADENITIS; SIDE EFFECT; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN DISEASE; STEVENS JOHNSON SYNDROME; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TOXIC HEPATITIS; TREATMENT DURATION; WEIGHT GAIN; COMPARATIVE STUDY; DRUG EFFECTS; FEMALE; INCIDENCE; LIVER; MALE; METABOLISM; PATHOPHYSIOLOGY; RISK ASSESSMENT; UNITED STATES;

ANTI-BACTERIAL AGENTS; ANTI-RETROVIRAL AGENTS; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; CHEMICAL AND DRUG INDUCED LIVER INJURY; DRUGS, INVESTIGATIONAL; FEMALE; HUMANS; INCIDENCE; LIVER; MALE; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT; UNITED STATES;

EID: 84991227337     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2016.08.009     Document Type: Review

References (132)

1. 1 Chalasani, N., Bonkovsky, H.L., Fontana, R., et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN Prospective Study. Gastroenterology 148:7 (2015), 1340–1352.e7.
2. 2 Farnsworth, N., Fagan, S.P., Berger, D.H., et al. Child-Turcotte-Pugh versus MELD score as a predictor of outcome after elective and emergent surgery in cirrhotic patients. Am J Surg 188:5 (2004), 580–583.
3. 3 Andrade, R.J., Lucena, M.I., Fernandez, M.C., et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 129:2 (2005), 512–521.
4. 4 Garcia Rodriguez, L.A., Stricker, B.H., Zimmerman, H.J., Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med 156:12 (1996), 1327–1332.
5. 5 O'Donohue, J., Oien, K.A., Donaldson, P., et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 47:5 (2000), 717–720.
6. 6 Stine, J.G., Lewis, J.H., Hepatotoxicity of antibiotics: a review and update for the clinician. Clin Liver Dis 17:4 (2013), 609–642 ix.
7. 7 Lucena, M.I., Molokhia, M., Shen, Y., et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 141:1 (2011), 338–347.
8. 8 Lucena, M.I., Andrade, R.J., Fernandez, M.C., et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology 44:4 (2006), 850–856.
9. 9 Thomson, J.A., Fairley, C.K., Ugoni, A.M., et al. Risk factors for the development of amoxycillin-clavulanic acid associated jaundice. Med J Aust 162:12 (1995), 638–640.
10. 10 de Abajo, F.J., Montero, D., Madurga, M., et al. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 58:1 (2004), 71–80.
11. 11 Reddy, K.R., Brillant, P., Schiff, E.R., Amoxicillin-clavulanate potassium-associated cholestasis. Gastroenterology 96:4 (1989), 1135–1141.
12. 12 Hautekeete, M.L., Horsmans, Y., Van Waeyenberge, C., et al. HLA association of amoxicillin-clavulanate–induced hepatitis. Gastroenterology 117:5 (1999), 1181–1186.
13. 13 Larrey, D., Vial, T., Micaleff, A., et al. Hepatitis associated with amoxycillin-clavulanic acid combination report of 15 cases. Gut 33:3 (1992), 368–371.
14. 14 Hautekeete, M.L., Brenard, R., Horsmans, Y., et al. Liver injury related to amoxycillin-clavulanic acid: interlobular bile-duct lesions and extrahepatic manifestations. J Hepatol 22:1 (1995), 71–77.
15. 15 Silvain, C., Fort, E., Levillain, P., et al. Granulomatous hepatitis due to combination of amoxicillin and clavulanic acid. Dig Dis Sci 37:1 (1992), 150–152.
16. 16 Alqahtani, S.A., Kleiner, D.E., Ghabril, M., et al. Identification and characterization of Cefazolin-induced liver injury. Clin Gastroenterol Hepatol 13:7 (2015), 1328–1336.e2.
17. 17 Bickford, C.L., Spencer, A.P., Biliary sludge and hyperbilirubinemia associated with ceftriaxone in an adult: case report and review of the literature. Pharmacotherapy 25:10 (2005), 1389–1395.
18. 18 Bor, O., Dinleyici, E.C., Kebapci, M., et al. Ceftriaxone-associated biliary sludge and pseudocholelithiasis during childhood: a prospective study. Pediatr Int 46:3 (2004), 322–324.
19. 19 Hopkins, S., Clinical toleration and safety of azithromycin. Am J Med 91:3A (1991), 40S–45S.
20. 20 Lockwood, A.M., Cole, S., Rabinovich, M., Azithromycin-induced liver injury. Am J Health Syst Pharm 67:10 (2010), 810–814.
21. 21 Longo, G., Valenti, C., Gandini, G., et al. Azithromycin-induced intrahepatic cholestasis. Am J Med 102:2 (1997), 217–218.
22. 22 Chandrupatla, S., Demetris, A.J., Rabinovitz, M., Azithromycin-induced intrahepatic cholestasis. Dig Dis Sci 47:10 (2002), 2186–2188.
23. 23 Martinez, M.A., Vuppalanchi, R., Fontana, R.J., et al. Clinical and histologic features of azithromycin-induced liver injury. Clin Gastroenterol Hepatol 13:2 (2015), 369–376.e3.
24. 24 Van Bambeke, F., Tulkens, P.M., Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf 32:5 (2009), 359–378.
25. 25 Paterson, J.M., Mamdani, M.M., Manno, M., et al. Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study. CMAJ 184:14 (2012), 1565–1570.
26. 26 Orman, E.S., Conjeevaram, H.S., Vuppalanchi, R., et al. Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol 9:6 (2011), 517–523.e3.
27. 27 Bataille, L., Rahier, J., Geubel, A., Delayed and prolonged cholestatic hepatitis with ductopenia after long-term ciprofloxacin therapy for Crohn's disease. J Hepatol 37:5 (2002), 696–699.
28. 28 Bjornsson, E., Olsson, R., Remotti, H., Norfloxacin-induced eosinophilic necrotizing granulomatous hepatitis. Am J Gastroenterol 95:12 (2000), 3662–3664.
29. 29 Surgers, L., Lacombe, K., Hepatoxicity of new antiretrovirals: a systematic review. Clin Res Hepatol Gastroenterol 37:2 (2013), 126–133.
30. 30 Nunez, M., Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology 52:3 (2010), 1143–1155.
31. 31 Cohen, C.J., Andrade-Villanueva, J., Clotet, B., et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 378:9787 (2011), 229–237.
32. 32 Molina, J.M., Cahn, P., Grinsztejn, B., et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 378:9787 (2011), 238–246.
33. 33 Katlama, C., Haubrich, R., Lalezari, J., et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS 23:17 (2009), 2289–2300.
34. 34 Ahmed, Y., Siddiqui, W., Enoch, C.B., et al. Rare case of rilpivirine-induced severe allergic hepatitis. J Antimicrob Chemother 68:2 (2013), 484–486.
35. 35 Mills, A.M., Nelson, M., Jayaweera, D., et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 23:13 (2009), 1679–1688.
36. 36 Vispo, E., Warning on hepatotoxicity of darunavir. AIDS Rev, 10(1), 2008, 63.
37. 37 Gulick, R.M., Lalezari, J., Goodrich, J., et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 359:14 (2008), 1429–1441.
38. 38 Sierra-Madero, J., Di Perri, G., Wood, R., et al. Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study. HIV Clin Trials 11:3 (2010), 125–132.
39. 39 Mangiafico, L., Perja, M., Fusco, F., et al. Safety and effectiveness of raltegravir in patients with haemophilia and anti-HIV multidrug resistance. Haemophilia 18:1 (2012), 108–111.
40. 40 Lennox, J.L., Dejesus, E., Berger, D.S., et al. Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 55:1 (2010), 39–48.
41. 41 Teppler, H., Brown, D.D., Leavitt, R.Y., et al. Long-term safety from the raltegravir clinical development program. Curr HIV Res 9:1 (2011), 40–53.
42. 42 Vispo, E., Mena, A., Maida, I., et al. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother 65:3 (2010), 543–547.
43. 43 Sax, P.E., DeJesus, E., Mills, A., et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 379:9835 (2012), 2439–2448.
44. 44 Raffi, F., Rachlis, A., Stellbrink, H.J., et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 381:9868 (2013), 735–743.
45. 45 Shah, R.R., Morganroth, J., Shah, D.R., Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf 36:7 (2013), 491–503.
46. 46 Iacovelli, R., Palazzo, A., Procopio, G., et al. Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy. Br J Clin Pharmacol 77:6 (2014), 929–938.
47. 47 O'Brien, S.G., Guilhot, F., Larson, R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:11 (2003), 994–1004.
48. 48 Bosutinib. Chronic myeloid leukaemia in treatment failure: major toxicity. Prescrire Int, 23(151), 2014, 177.
49. 49 Gambacorti-Passerini, C., Cortes, J.E., Lipton, J.H., et al. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol 89:10 (2014), 947–953.
50. 50 Singer, J.B., Shou, Y., Giles, F., et al. UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia 21:11 (2007), 2311–2315.
51. 51 Bonvin, A., Mesnil, A., Nicolini, F.E., et al. Dasatinib-induced acute hepatitis. Leuk Lymphoma 49:8 (2008), 1630–1632.
52. 52 Carlini, P., Papaldo, P., Fabi, A., et al. Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450?. J Clin Oncol 24:35 (2006), e60–e61.
53. 53 Ho, C., Davis, J., Anderson, F., et al. Side effects related to cancer treatment: CASE 1. Hepatitis following treatment with gefitinib. J Clin Oncol 23:33 (2005), 8531–8533.
54. 54 Shepherd, F.A., Rodrigues Pereira, J., Ciuleanu, T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:2 (2005), 123–132.
55. 55 Arora, A.K., Erlotinib-induced Hepatotoxicity-Clinical presentation and successful management: a case report. J Clin Exp Hepatol 1:1 (2011), 38–40.
56. 56 Llovet, J.M., Ricci, S., Mazzaferro, V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:4 (2008), 378–390.
57. 57 Van Hootegem, A., Verslype, C., Van Steenbergen, W., Sorafenib-induced liver failure: a case report and review of the literature. Case Reports Hepatol, 2011, 2011, 941395.
58. 58 Mueller, E.W., Rockey, M.L., Rashkin, M.C., Sunitinib-related fulminant hepatic failure: case report and review of the literature. Pharmacotherapy 28:8 (2008), 1066–1070.
59. 59 Klempner, S.J., Choueiri, T.K., Yee, E., et al. Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients. J Clin Oncol 30:27 (2012), e264–e268.
60. 60 Kapadia, S., Hapani, S., Choueiri, T.K., et al. Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients. Acta Oncol 52:6 (2013), 1202–1212.
61. 61 Shamroe, C.L., Comeau, J.M., Ponatinib: a new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Ann Pharmacother 47:11 (2013), 1540–1546.
62. 62 Peroukides, S., Makatsoris, T., Koutras, A., et al. Lapatinib-induced hepatitis: a case report. World J Gastroenterol 17:18 (2011), 2349–2352.
63. 63 Spraggs, C.F., Budde, L.R., Briley, L.P., et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol 29:6 (2011), 667–673.
64. 64 Ribas, A., Hodi, F.S., Callahan, M., et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 368:14 (2013), 1365–1366.
65. 65 Teo, Y.L., Ho, H.K., Chan, A., Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review. Expert Opin Drug Metab Toxicol 11:2 (2015), 231–242.
66. 66 Bunchorntavakul, C., Reddy, K.R., Acetaminophen-related hepatotoxicity. Clin Liver Dis 17:4 (2013), 587–607 viii.
67. 67 Karczmarek-Borowska, B., Salek-Zan, A., Hepatotoxicity of molecular targeted therapy. Contemp Oncol (Pozn) 19:2 (2015), 87–92.
68. 68 Robinson, S.M., Wilson, C.H., Burt, A.D., et al. Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann Surg Oncol 19:13 (2012), 4287–4299.
69. 69 Zalinski, S., Bigourdan, J.M., Vauthey, J.N., Does bevacizumab have a protective effect on hepatotoxicity induced by chemotherapy?. J Chir (Paris) 147:Suppl 1 (2010), S18–S24 [in French].
70. 70 Ishizuna, K., Ninomiya, J., Ogawa, T., et al. Hepatotoxicity induced by trastuzumab used for breast cancer adjuvant therapy: a case report. J Med Case Rep, 8, 2014, 417.
71. 71 Srinivasan, S., Parsa, V., Liu, C.Y., et al. Trastuzumab-induced hepatotoxicity. Ann Pharmacother 42:10 (2008), 1497–1501.
72. 72 Cobleigh, M.A., Vogel, C.L., Tripathy, D., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:9 (1999), 2639–2648.
73. 73 Verma, S., Miles, D., Gianni, L., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:19 (2012), 1783–1791.
74. 74 Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer. Med Lett Drugs Ther 55:1425 (2013), 75–76.
75. 75 Force, J., Saxena, R., Schneider, B.P., et al. Nodular regenerative hyperplasia after treatment with trastuzumab emtansine. J Clin Oncol 34:3 (2016), e9–e12.
76. 76 Bahirwani, R., Reddy, K.R., Drug-induced liver injury due to cancer chemotherapeutic agents. Semin Liver Dis 34:2 (2014), 162–171.
77. 77 Wolchok, J.D., Neyns, B., Linette, G., et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11:2 (2010), 155–164.
78. 78 Weber, J.S., Kahler, K.C., Hauschild, A., Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30:21 (2012), 2691–2697.
79. 79 Robert, C., Thomas, L., Bondarenko, I., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:26 (2011), 2517–2526.
80. 80 Johncilla, M., Misdraji, J., Pratt, D.S., et al. Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases. Am J Surg Pathol 39:8 (2015), 1075–1084.
81. 81 Sarin, S.K., Kumar, M., Lau, G.K., et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 10:1 (2016), 1–98.
82. 82 Reddy, K.R., Beavers, K.L., Hammond, S.P., et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 148:1 (2015), 215–219 [quiz: e216–7].
83. 83 Bjornsson, E.S., Gunnarsson, B.I., Grondal, G., et al. Risk of drug-induced liver injury from tumor necrosis factor antagonists. Clin Gastroenterol Hepatol 13:3 (2015), 602–608.
84. 84 Sokolove, J., Strand, V., Greenberg, J.D., et al. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis 69:9 (2010), 1612–1617.
85. 85 Ghabril, M., Bonkovsky, H.L., Kum, C., et al. Liver injury from tumor necrosis factor-alpha antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol 11:5 (2013), 558–564.e3.
86. 86 Carroll, M.B., Forgione, M.A., Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol 29:9 (2010), 1021–1029.
87. 87 Bauer, K.A., Pros and cons of new oral anticoagulants. Hematology Am Soc Hematol Educ Program 2013 (2013), 464–470.
88. 88 Lee, W.M., Larrey, D., Olsson, R., et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf 28:4 (2005), 351–370.
89. 89 Liakoni, E., Ratz Bravo, A.E., Krahenbuhl, S., Hepatotoxicity of New Oral Anticoagulants (NOACs). Drug Saf 38:8 (2015), 711–720.
90. 90 Caldeira, D., Barra, M., Santos, A.T., et al. Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis. Heart 100:7 (2014), 550–556.
91. 91 Raschi, E., Poluzzi, E., Koci, A., et al. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system. Br J Clin Pharmacol 80:2 (2015), 285–293.
92. 92 Russmann, S., Niedrig, D.F., Budmiger, M., et al. Rivaroxaban postmarketing risk of liver injury. J Hepatol 61:2 (2014), 293–300.
93. 93 Liakoni, E., Ratz Bravo, A.E., Terracciano, L., et al. Symptomatic hepatocellular liver injury with hyperbilirubinemia in two patients treated with rivaroxaban. JAMA Intern Med 174:10 (2014), 1683–1686.
94. 94 Lambert, A., Cordeanu, M., Gaertner, S., et al. Rivaroxaban-induced liver injury: results from a venous thromboembolism registry. Int J Cardiol 191 (2015), 265–266.
95. 95 Barrett, P., Vuppalanchi, R., Masuoka, H., et al. Severe drug-induced skin and liver injury from rivaroxaban. Dig Dis Sci 60:6 (2015), 1856–1858.
96. 96 Steinhubl, S.R., Berger, P.B., Mann, J.T. 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288:19 (2002), 2411–2420.
97. 97 Yusuf, S., Zhao, F., Mehta, S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:7 (2001), 494–502.
98. 98 Beltran-Robles, M., Marquez Saavedra, E., Sanchez-Munoz, D., et al. Hepatotoxicity induced by clopidogrel. J Hepatol 40:3 (2004), 560–562.
99. 99 Hollmuller, I., Stadlmann, S., Graziadei, I., et al. Clinico-histopathological characteristics of clopidogrel-induced hepatic injury: case report and review of literature. Eur J Gastroenterol Hepatol 18:8 (2006), 931–934.
100. 100 Kohli, P., Udell, J.A., Murphy, S.A., et al. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). J Am Coll Cardiol 63:3 (2014), 225–232.
101. 101 Serebruany, V.L., Kipshidze, N., Pershukov, I.V., et al. Fatal sepsis and systemic inflammatory response syndrome after off-label prasugrel: a case report. Am J Ther 21:6 (2014), e229–e233.
102. 102 Tella, S.H., Rendell, M.S., DPP-4 inhibitors: focus on safety. Expert Opin Drug Saf 14:1 (2015), 127–140.
103. 103 Scheen, A.J., Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease. Expert Opin Drug Metab Toxicol 10:6 (2014), 839–857.
104. 104 Engel, S.S., Round, E., Golm, G.T., et al. Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies. Diabetes Ther 4:1 (2013), 119–145.
105. 105 Ligueros-Saylan, M., Foley, J.E., Schweizer, A., et al. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of phase II and III clinical trials. Diabetes Obes Metab 12:6 (2010), 495–509.
106. 106 Gross, B.N., Cross, L.B., Foard, J., et al. Elevated hepatic enzymes potentially associated with sitagliptin. Ann Pharmacother 44:2 (2010), 394–395.
107. 107 Toyoda-Akui, M., Yokomori, H., Kaneko, F., et al. A case of drug-induced hepatic injury associated with sitagliptin. Intern Med 50:9 (2011), 1015–1020.
108. 108 Kurita, N., Ito, T., Shimizu, S., et al. Idiosyncratic liver injury induced by vildagliptin with successful switch to linagliptin in a hemodialyzed diabetic patient. Diabetes Care 37:9 (2014), e198–e199.
109. 109 Barbehenn, E., Almashat, S., Carome, M., et al. Hepatotoxicity of alogliptin. Clin Pharmacokinet 53:11 (2014), 1055–1056.
110. 110 Kutoh, E., Probable linagliptin-induced liver toxicity: a case report. Diabetes Metab 40:1 (2014), 82–84.
111. 111 Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000771/WC500020327.pdf. Accessed April 14, 2016.
112. 112 Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002182/WC500152273.pdf. Accessed April 14, 2016.
113. 113 Armstrong, M.J., Houlihan, D.D., Rowe, I.A., et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program. Aliment Pharmacol Ther 37:2 (2013), 234–242.
114. 114 Zhang, M., Zhang, L., Wu, B., et al. Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev 30:3 (2014), 204–221.
115. 115 Devarbhavi, H., Andrade, R.J., Drug-induced liver injury due to antimicrobials, central nervous system agents, and nonsteroidal anti-inflammatory drugs. Semin Liver Dis 34:2 (2014), 145–161.
116. 116 Johannessen, S.I., Landmark, C.J., Antiepileptic drug interactions - principles and clinical implications. Curr Neuropharmacol 8:3 (2010), 254–267.
117. 117 Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020189s022lbl.pdf. Accessed September 16, 2016.
118. 118 Amante, M.F., Filippini, A.V., Cejas, N., et al. Dress syndrome and fulminant hepatic failure induced by lamotrigine. Ann Hepatol 8:1 (2009), 75–77.
119. 119 Ouellet, G., Tremblay, L., Marleau, D., Fulminant hepatitis induced by lamotrigine. South Med J 102:1 (2009), 82–84.
120. 120 Tan, T.C., de Boer, B.W., Mitchell, A., et al. Levetiracetam as a possible cause of fulminant liver failure. Neurology 71:9 (2008), 685–686.
121. 121 Ragucci, M.V., Cohen, J.M., Gabapentin-induced hypersensitivity syndrome. Clin Neuropharmacol 24:2 (2001), 103–105.
122. 122 Dogan, S., Ozberk, S., Yurci, A., Pregabalin-induced hepatotoxicity. Eur J Gastroenterol Hepatol, 23(7), 2011, 628.
123. 123 Einarsdottir, S., Bjornsson, E., Pregabalin as a probable cause of acute liver injury. Eur J Gastroenterol Hepatol, 20(10), 2008, 1049.
124. 124 Planjar-Prvan, M., Bielen, A., Sruk, A., et al. Acute oxcarbazepine-induced hepatotoxicity in a patient susceptible to developing drug-induced liver injury. Coll Antropol 37:1 (2013), 281–284.
125. 125 Sethi, N.K., Sethi, P.K., Torgovnick, J., et al. Asymptomatic elevation of liver enzymes due to levetiracetam: a case report. Drug Metabol Drug Interact 28:2 (2013), 123–124.
126. 126 Voican, C.S., Corruble, E., Naveau, S., et al. Antidepressant-induced liver injury: a review for clinicians. Am J Psychiatry 171:4 (2014), 404–415.
127. 127 Spigset, O., Hagg, S., Bate, A., Hepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors: data from the World Health Organization (WHO) database of adverse drug reactions. Int Clin Psychopharmacol 18:3 (2003), 157–161.
128. 128 Wernicke, J., Pangallo, B., Wang, F., et al. Hepatic effects of duloxetine-I: non-clinical and clinical trial data. Curr Drug Saf 3:2 (2008), 132–142.
129. 129 Xue, F., Strombom, I., Turnbull, B., et al. Duloxetine for depression and the incidence of hepatic events in adults. J Clin Psychopharmacol 31:4 (2011), 517–522.
130. 130 McIntyre, R.S., Panjwani, Z.D., Nguyen, H.T., et al. The hepatic safety profile of duloxetine: a review. Expert Opin Drug Metab Toxicol 4:3 (2008), 281–285.
131. 131 Kim, M.S., Kim, S.W., Han, T.Y., et al. Ziprasidone-induced hypersensitivity syndrome confirmed by reintroduction. Int J Dermatol 53:4 (2014), e267–e268.
132. 132 Parsons, B., Allison, D.B., Loebel, A., et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res 110:1–3 (2009), 103–110.